Efficacy and biomarker analysis of carboplatin plus taxanes neoadjuvant chemotherapy in triple-negative breast cancer: A prospective multicenter cohort study.

作者
Xi Chen,Meng Xiu,Hua Kang,Yan Zhang,Hua Yang,Xueyan Cheng,Qiao Li,Qing Li,Jiayu Wang,Bo Lan,Shanshan Chen,Min Xiao,Xiaoyan Qian,Bin Hua,Binghe Xu,Pin Zhang
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:42 (16_suppl): e12619-e12619
标识
DOI:10.1200/jco.2024.42.16_suppl.e12619
摘要

e12619 Background: The efficacy and survival data of carboplatin plus taxane (anthracycline-free) neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) was lack of a large-sample study. The predictive biomarker of efficacy based on cell-free DNA (cfDNA) whole-methylome sequencing (WMS) has not been reported yet. Methods: The prospective multi-center cohort study was conducted in four hospitals of Chinabetween 2016 and 2023. Stage II-III TNBC patients were enrolled to receive NAC of carboplatin (AUC 5) every 3 weeks or carboplatin (AUC 4) every 2 weeks plus taxane(standard dose) for 4-6 cycles. Primary study endpoint were pathological complete response (pCR) and relapse-free survival (RFS). Plasma samples were prospectively collected at baseline (T1) and after NAC(T2). Chromosomal aneuploidy of featured fragments (CAFF),fragment size index (FSI) and methylation density score (MD) of cfDNA were detected with WMS. Results: A total of 267 patients were included in the study. The median age was 49 years, 156 patients (58.4%) were stage III disease. 147 patients (55.1%) received the triweekly NAC. 263 patients underwent breast surgery after NAC and 106 patients (40.3%) achieved pCR. The pCR were similar in biweekly or triweekly groups (39.8% vs 40.7%, P=0.89). The 3-year RFS and overall survival (OS) were 77.9%, 87.6%, respectively. Patients who achieved pCR had a significant better RFS (95.5%) and OS (97.7%) than those non-pCR (76.6%, P<0.001; 81.2%, P<0.001). A total of 66 patients with 120 plasma samples (64 samples at T1, 56 samples at T2) were included in WMS analysis. Patients with CAFF, FSI or MD positive at T1 had a higher tumor burden (stage III or cN2-3, all P values <0.05). The proportion of patients with FSI negative at T2 was significantly higher in pCR group compared to non-pCR(86.2% vs 59.3%, P=0.034). There is a similar tendency in patients with CAFF negative. Patients with MD positive at T1 was significantly associated with poor RFS compared to MD negative (HR = 7.36, 95% CI: 0.93-58.75, Log-rank P=0.028). A linear SVM model based on FSI, CAFF, combining with immune cell (effector memory CD8 T cells, immature B cells) and clinical features was developed to predict pCR, with AUC = 0.90 for training dataset and AUC = 0.86 for testing data. Conclusions: Our large-sample study further confirmed that carboplatin plus taxanes (anthracycline-free) NAC in TNBC is an effective option with clinical applicability. Biomarkers based on cfDNA WMS may offer some predictive and prognostic value which needed to be further investigated.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
灵巧的嚣完成签到,获得积分10
刚刚
欣喜书易完成签到 ,获得积分10
刚刚
cdercder的应助被钟嘉霖采纳,获得10
1秒前
1秒前
2秒前
2秒前
anyuezou完成签到,获得积分10
2秒前
竹蜻蜓发布了新的文献求助10
3秒前
e00ec发布了新的文献求助10
4秒前
彭于晏的应助被12采纳,获得10
4秒前
fy完成签到,获得积分10
6秒前
ecauscibe完成签到,获得积分10
7秒前
秋秋发布了新的文献求助10
7秒前
诚心的志泽完成签到,获得积分10
7秒前
9秒前
9秒前
10秒前
ding的应助被zgm采纳,获得10
10秒前
Khalil完成签到,获得积分10
11秒前
13秒前
14秒前
16秒前
煜猪猪完成签到,获得积分10
16秒前
16秒前
necos发布了新的文献求助10
17秒前
chiaugustus发布了新的文献求助10
18秒前
yy完成签到,获得积分10
19秒前
隐隐完成签到,获得积分10
19秒前
zww发布了新的文献求助10
19秒前
20秒前
生尽证提发布了新的文献求助10
20秒前
20秒前
22秒前
核桃发布了新的文献求助10
23秒前
24秒前
lin完成签到,获得积分10
25秒前
德烁发布了新的文献求助10
25秒前
25秒前
25秒前
无极微光的应助被zxh_采纳,获得20
26秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8192903
求助须知:如何正确求助?哪些是违规求助? 9579325
关于积分的说明 21864493
捐赠科研通 7792494
什么是DOI,文献DOI怎么找? 3437087
关于科研通互助平台的介绍 2560652
邀请新用户注册赠送积分活动 2483937